← Back to Search

Enzyme Inhibitor

PCNA Inhibitor AOH1996 for Cancer

Phase 1
Waitlist Available
Led By Vincent Chung
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Life expectancy of > 3 months
Patients with solid tumors failing standard therapies or patients refusing standard treatments
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial is testing AOH1996 to see if it can help patients with solid tumors that haven't responded to other treatments. AOH1996 may work by blocking some of the enzymes needed for cell growth.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are expected to live for more than 3 months.
Select...
You have a type of cancer that has not responded to regular treatments, or you have chosen not to receive standard treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose limiting toxicities
Incidence of adverse events (AEs)
Secondary outcome measures
Overall survival
Progression-free survival
Response rate
+1 more
Other outcome measures
Levels of plasma gammaH2AX

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (PCNA inhibitor AOH1996)Experimental Treatment1 Intervention
Patients receive PCNA inhibitor AOH1996 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
558 Previous Clinical Trials
1,917,397 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,603 Previous Clinical Trials
40,913,221 Total Patients Enrolled
Vincent ChungPrincipal InvestigatorCity of Hope Medical Center
9 Previous Clinical Trials
355 Total Patients Enrolled

Media Library

AOH1996 (Enzyme Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05227326 — Phase 1
Solid Tumors Research Study Groups: Treatment (PCNA inhibitor AOH1996)
Solid Tumors Clinical Trial 2023: AOH1996 Highlights & Side Effects. Trial Name: NCT05227326 — Phase 1
AOH1996 (Enzyme Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05227326 — Phase 1
Solid Tumors Patient Testimony for trial: Trial Name: NCT05227326 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are medical centers currently signing up participants for this clinical investigation?

"Affirmative. Clinicaltrials.gov data indicates that the medical trial, which was first advertised on August 12th 2022, is still recruiting participants. Approximately 8 patients must be sourced from 2 different clinical sites."

Answered by AI

Has the Food and Drug Administration officially sanctioned Treatment (PCNA inhibitor AOH1996)?

"As this is a preliminary Phase 1 trial, the safety of treatment (PCNA inhibitor AOH1996) was deemed to be low and thus received a score of 1."

Answered by AI

To what extent is recruitment ongoing for this research endeavor?

"Yes, the information posted on clinicaltrials.gov appears to confirm that this medical experiment is actively seeking participants. This trial had its inception on August 12th 2022 and was recently updated on September 29th 2022. They are looking for 8 individuals across 2 research sites."

Answered by AI

What are the principal aims of this exploration?

"The primary endpoint of this medical trial is to evaluate dose-limiting toxicities over a 30 day period post-treatment. Secondary endpoints include response rate (as assessed with RECIST v1), progression free survival, and time to treatment failure."

Answered by AI

Who else is applying?

What state do they live in?
Hawaii
Texas
New York
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
3+
1
2
What site did they apply to?
HonorHealth Research Institute
City of Hope Medical Center

Why did patients apply to this trial?

Because glioblastoma is untreatable with current medication. I would like to avoid life altering surgery if at all possible.
PatientReceived 2+ prior treatments
I have glioblastoma,I’ve tried temozolomide but the tumor is getting worse.
PatientReceived 1 prior treatment
currently getting sunitinib for my metastased kidney cancer on my spine (L1 disk).
PatientReceived 2+ prior treatments
I tried multiple alternative-treatments because no 1st line treatment had good chances of helping.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

Only one, is it possible for persons from Serbia ? Can you please provide how it works with the timeline?
PatientReceived 1 prior treatment
1. Is the new molecule AOH1996 effective against glioblasoma multiform grade IV?
PatientReceived no prior treatments
I’m not in a 100% normal mental state because of the brain tumor that I have,Will that cause any problems with the trial ?
PatientReceived no prior treatments

How responsive is this trial?

Most responsive sites:
  1. HonorHealth Research Institute: < 48 hours
Typically responds via
Email
Average response time
  • < 2 Days
~11 spots leftby Sep 2024